Long-term outcome of patients with ulcerative colitis and primary non-response to infliximab

Journal of Crohn's and Colitis

Volumn 10, Issue 9, 2016, Pages 1015-1023

  Papamichael, Konstantinos ^a,b   Rivals Lerebours, Oliviane ^c   Billiet, Thomas ^a   Casteele, Niels Vande ^d   Gils, Ann ^d   Ferrante, Marc ^a   Assche, Gert Van ^a   Rutgeerts, Paul J ^a   Mantzaris, Gerassimos J ^b   Peyrin Biroulet, Laurent ^c   Vermeire, Severine ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b EVANGELISMOS HOSPITAL   (Greece)

^c UNIVERSITY HOSPITAL OF NANCY   (France)

^d DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

Author keywords

Drug concentrations; Infliximab; Primary non response; Ulcerative colitis

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; INFLIXIMAB; VEDOLIZUMAB; GASTROINTESTINAL AGENT;

ADULT; ARTICLE; CLINICAL PRACTICE; COLON RESECTION; COMPARATIVE STUDY; CORTICOSTEROID THERAPY; DISEASE DURATION; DRUG BLOOD LEVEL; DRUG RESPONSE; ELECTRONIC MEDICAL RECORD; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEALTH CARE QUALITY; HUMAN; IMMUNOADSORPTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT REFERRAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIGMOIDOSCOPY; TREATMENT RESPONSE; ULCERATIVE COLITIS; BLOOD; CLINICAL TRIAL; COLITIS, ULCERATIVE; INDUCTION CHEMOTHERAPY; KAPLAN MEIER METHOD; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; RISK FACTOR; TREATMENT FAILURE;

ADULT; COLECTOMY; COLITIS, ULCERATIVE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; HUMANS; INDUCTION CHEMOTHERAPY; INFLIXIMAB; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT FAILURE;

EID: 85012302479     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1093/ecco-jcc/jjw067     Document Type: Article

References (42)

1. Billiet T, Rutgeerts P, Ferrante M, et al. Targeting TNFα for the treatment of inflammatory bowel disease. Expert Opin Biol Ther 2014;14:75-101.
2. Ben-Horin S, Chowers Y. Tailoring anti-TNF therapy in IBD: drug levels and disease activity. Nat Rev Gastroenterol Hepatol 2014;11:243-55.
3. Allez M, Karmiris K, Louis E, et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis 2010;4:355-66.
4. Ben-Horin S, Kopylov U, Chowers Y. Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev 2014;13:24-30.
5. Papamichael K, Gils A, Rutgeerts P, et al. Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary non response. Inflamm Bowel Dis 2015;21:182-97.
6. Seiderer J, Brand S, Dambacher J, et al. Adalimumab in patients with Crohn's disease safety and efficacy in an open-label single centre study. Aliment Pharmacol Ther 2007;25:787-96.
7. Chaparro M, Andreu M, Barreiro-de Acosta M, et al. Effectiveness of infliximab after adalimumab failure in Crohn's disease. World J Gastroenterol 2012;18:5219-24.
8. Ho GT, Mowat A, Potts L, et al. Efficacy and complications of adalimumab treatment for medically-refractory Crohn's disease: analysis of nationwide experience in Scotland [2004-2008]. Aliment Pharmacol Ther 2009;29:527-34.
9. Danese S, Mocciaro F, Guidi L, et al. Successful induction of clinical response and remission with certolizumab pegol in Crohn's disease patients refractory or intolerant to infliximab: a real-life multicentre experience of compassionate use. Inflamm Bowel Dis 2008;14:1168-70.
10. Gisbert JP, Chaparro M. Use of a third anti-TNF after failure of two previous anti-TNFs in patients with inflammatory bowel disease: is it worth it? Scand J Gastroenterol 2015;50:379-86.
11. Gisbert JP, Marín AC, McNicholl AG, Chaparro M. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. Aliment Pharmacol Ther 2015;41:613-23.
12. Adedokun OJ, Sandborn WJ, Feagan BG, et al. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. Gastroenterology 2014;147:1296-307.
13. Cornillie F, Hanauer SB, Diamond RH, et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut 2014;63:1721-7.
14. Baert F, Vande Casteele N, Tops S, et al. Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis. Aliment Pharmacol Ther 2014;40:1324-32.
15. Brandse JF, van den Brink GR, Wildenberg ME, et al. Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis. Gastroenterology 2015;149:350-5
16. Papamichael K, Van Stappen T, Vande Casteele N. Infliximab concentration thresholds during induction therapy are associated with short-term mucosal healing in patients with ulcerative colitis. Clin Gastroenterol Hepatol 2016;14:5439.
17. Arias MT, Vande Casteele N, Vermeire S, et al. A panel to predict longterm outcome of infliximab therapy for patients with ulcerative colitis. Clin Gastroenterol Hepatol 2015;13:531-8.
18. Bortlik M, Duricova D, Malickova K, et al. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease. J Crohns Colitis 2013;7:736-43.
19. Yanai H, Lichtenstein L, Assa A, et al. Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab. Clin Gastroenterol Hepatol 2015;13:522-30.
20. Danese S, Vuitton L, Peyrin-Biroulet L. Biologic agents for IBD: practical insights. Nat Rev Gastroenterol Hepatol 2015;12:537-45.
21. Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a singlecentre cohort. Gut 2009;58:492-500.
22. Vande Casteele N, Buurman DJ, Sturkenboom MG, et al. Detection of infliximab concentrations and anti-infliximab antibodies: a comparison of three different assays. Aliment Pharmacol Ther 2012;36:765-71.
23. Ordas I, Mould DR, Feagan BG, et al. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther 2012;91: 635-46.
24. Fasanmade AA, Adedokun OJ, Olson A, et al. Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis. Int J Clin Pharmacol Ther 2010;48:297-308.
25. Dotan I, Ron Y, Yanai H, et al. Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study. Inflamm Bowel Dis 2014;20:2247-59.
26. Seow CH, Newman A, Irwin SP, et al. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010;59:49-54.
27. Yarur AJ, Rubin DT. Therapeutic drug monitoring of anti-tumor necrosis factor agents in patients with inflammatory bowel diseases. Inflamm Bowel Dis 2015;21:1709-18.
28. Rosen MJ, Minar P, Vinks AA. Review article: applying pharmacokinetics to optimise dosing of anti-TNF biologics in acute severe ulcerative colitis. Aliment Pharmacol Ther 2015;41:1094-103.
29. Gibson DJ, Heetun ZS, Redmond CE, et al. An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol 2015;13:330-5.
30. Hendler SA, Cohen BL, Colombel JF, et al. High-dose infliximab therapy in Crohn's disease: clinical experience, safety, and efficacy. J Crohns Colitis 2015;9:266-75.
31. Yarur AJ, Jain A, Sussman DA, et al. The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study. Gut 2016;65:249-55.
32. Brandse JF, Mathôt RA, van der Kleij D, et al. Pharmacokinetic features and presence of antidrug antibodies associate with response to infliximab induction therapy in patients with moderate to severe ulcerative colitis. Clin Gastroenterol Hepatol 2016;14:251-8.
33. Leal RF, Planell N, Kajekar R, et al. Identification of inflammatory mediators in patients with Crohn's disease unresponsive to anti-TNFa therapy. Gut 2015;64:233-42.
34. Arijs I, Quintens R, Van Lommel L, et al. Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's disease. Inflamm Bowel Dis 2010;16:2090-8.
35. Arijs I, Li K, Toedter G, et al. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut 2009;58:1612-9.
36. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369:699-710.
37. Nestorov I. Clinical pharmacokinetics of tumor necrosis factor antagonists. J Rheumatol Suppl. 2005;74:13-8.
38. Slevin SM, Egan LJ. New insights into the mechanisms of action of antitumor necrosis factor-a monoclonal antibodies in inflammatory bowel disease. Inflamm Bowel Dis 2015;21: 2909-20.
39. Du Pan SM, Scherer A, Gabay C, Finckh A. Differential drug retention between anti-TNF agents and alternative biological agents after inadequate response to an anti-TNF agent in rheumatoid arthritis patients. Ann Rheum Dis 2012;71:997-9.
40. Finckh A, Ciurea A, Brulhart L, et al. Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor [TNF] agents after previous failure of an anti-TNF agent? Ann Rheum Dis 2010;69:387-93.
41. Bryant RV, Sandborn WJ, Travis SP. Introducing vedolizumab to clinical practice: who, when, and how? J Crohns Colitis 2015;9:356-66.
42. Dignass A, Eliakim R, Magro F, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: defintions and diagnosis. J Crohn's Colitis 2012;6:965-990.